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Translational relevance 
The Ras/Raf/MEK/ERK pathway is a key signaling cascade driving cell cycle proliferation, 
differentiation and survival. Activations in this pathway contribute to malignant progression in 
many human cancers. Selumetinib (AZD6244/ARRY-142886) is an oral inhibitor of MEK1/2 
currently in clinical development for a number of tumor types. Preclinical studies have 
demonstrated antitumor activity of selumetinib in melanoma xenograft models particularly 
those harboring BRAF mutations. In this study there was no significant difference in efficacy 
between the selumetinib and temozolomide as first-line therapy for patients with advanced 
melanoma not selected for activating BRAFmutations. Of note, five of the six patients 
showing partial response with selumetinib had tumors that were BRAF mutant. Based on 
these results, and preclinical data, a phase II study of selumetinib in combination with 
chemotherapy for patients with BRAF-mutated melanoma has been initiated. 
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Abstract  
Purpose: To compare the efficacy and tolerability of the MEK 1/2 inhibitor selumetinib 
versus temozolomide in chemotherapy-naïve patients with unresectable stage III/IV 
melanoma. 
Methods: This phase II, open-label, multicenter, randomized, parallel-group study examined 
the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide 
(200 mg/m2/day for 5 days, then 23 days off treatment). The primary endpoint was 
progression-free survival. 
Results: Two hundred patients were randomized. Progression-free survival did not differ 
significantly between selumetinib and temozolomide (median time to event 78 and 80 days, 
respectively; hazard ratio, 1.07; 80% confidence interval, 0.86–1.32). Objective response 
was observed in six (5.8%) patients receiving selumetinib and nine (9.4%) patients in the 
temozolomide group. Among patients with BRAF mutations, objective responses were 
similar between selumetinib and temozolomide groups (11.1% and 10.7%, respectively). 
However, five of the six selumetinib partial responders were BRAF mutated. Frequently 
reported adverse events with selumetinib were dermatitis acneiform (papular pustular rash; 
59.6%), diarrhea (56.6%), nausea (50.5%) and peripheral edema (40.4%), whereas nausea 
(64.2%), constipation (47.4%) and vomiting (44.2%) were reported with temozolomide.  
Conclusions: No significant difference in progression-free survival was observed between 
patients with unresectable stage III/IV melanoma unselected for BRAF/NRAS mutations, 
who received therapy with selumetinib or temozolomide. Five of six patients with partial 
response to selumetinib had BRAF mutant tumors.  
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Introduction 
The Ras/Raf/MEK/ERK pathway is a key signaling cascade driving cell cycle proliferation, 
differentiation and survival (1, 2). Mutations affecting signaling molecules, including Ras and 
Raf, activate this pathway and contribute to malignant progression in many human cancers 
(3-6). BRAF and NRAS mutations are generally mutually exclusive in melanoma (7, 8). At 
the time of study initiation the mutation frequencies for BRAF and NRAS were estimated as 
59% (9) and 30% (10) respectively. However, recent estimates suggest that the frequency 
for BRAF mutations may be as low as 41% (11).  
Agents targeting mutated BRAF are in development (12, 13); however, they may be 
associated with paradoxical activation of the MAPK pathway in BRAF wild-type cells (14). 
MEK1/2 is an attractive therapeutic target due to its key position within the 
Ras/Raf/MEK/ERK pathway (2, 15) and paradoxical activation effects are not expected with 
MEK inhibitors. Selumetinib (AZD6244/ARRY-142886) is an orally available, potent, 
selective, allosteric inhibitor of MEK1/2 with preclinical antitumor activity in melanoma (16), 
which has been shown to inhibit the growth of cell lines expressing BRAF V600E mutation 
(17, 18). 
In a phase I trial of selumetinib including patients with melanoma (20/57 patients, 35%), 
prolonged stable disease (SD) ≥5 months was observed in nine patients (16%) (19). The 
maximum tolerated dose of selumetinib was determined as 200 mg BID however, the dose 
chosen for ongoing phase II studies was 100 mg BID due to the frequency of treatment-
related rash with chronic administration. Consistent inhibition of ERK phosphorylation shown 
between pre- and post-treatment biopsies demonstrated that this dose results in target 
inhibition. This study also showed that selumetinib 100mg BID was considered to have a 
manageable toxicity profile. 
The current study compared the efficacy of orally administered selumetinib and 
temozolomide (TMZ) in chemotherapy-naïve patients with advanced melanoma. It is the first 
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multicenter, randomized study conducted in patients with melanoma assessed for both 
BRAF and NRAS mutations. At the time of initiation there was no global standard of care for 
chemotherapy-naïve advanced melanoma patients, therefore TMZ was chosen as 
comparator for this study because it had been used in both clinical trials and was licensed 
for this indication in some countries (20). In addition, TMZ has the same active metabolite (5-
[3-methyl-1-triazeno]imidazole-4-carboxamide) as dacarbazine, an approved treatment for 
advanced melanoma, but TMZ has the benefit of being administered orally. The dose of 
TMZ (200 mg/m2/day for 5 days, followed by 23 days off treatment) used in the present 
study is the recommended monotherapy dose (21) which was used in a large phase III study 
in patients with advanced melanoma (22). 
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Methods 
This phase II, open-label, multicenter, randomized, parallel-group study (clinicaltrials.gov 
registry number NCT00338130) enrolled patients without previous systemic chemotherapy 
for advanced melanoma between July 2006 and June 2007, and was conducted in 
accordance with good clinical practice guidelines and the Declaration of Helsinki. Thirty-four 
centers from 10 countries participated in this trial: Argentina (3 centers), Australia (3), Austria 
(2), Brazil (6), Canada (2), Denmark (1), France (3), Switzerland (1), the United Kingdom (3) 
and United States (10). 
Patient selection 
All included patients provided written informed consent and fulfilled the following criteria: age 
≥18 years, histologic or cytologic confirmation of unresectable American Joint Committee on 
Cancer (AJCC) stage III or IV malignant melanoma, at least one measurable site of disease 
defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, World 
Health Organization (WHO) performance status 0–2 and willingness to provide tumor biopsy 
(fresh or archival) for determination of BRAF and NRAS mutation status. Female patients 
were required to have a negative pregnancy test or be postmenopausal. To be 
representative of the general melanoma population, the number of uveal melanoma patients 
was limited to 20 of the planned 182. 
Exclusion criteria included absolute neutrophil count <1,500/mm3, platelets <100,000/mm3, 
hemoglobin ≤9 g/dL, serum creatinine clearance ≤30 mL/min, serum bilirubin ≥1.5 x upper 
limit of normal (ULN), aspartate aminotransferase ≥2.5 x ULN, alanine aminotransferase 
≥2.5 x ULN or serum creatinine ≥1.5 mg/dL, chemotherapy or radiotherapy within 5 years 
prior to start of study treatment (excluding palliative radiotherapy at focal sites), any systemic 
chemotherapy for unresectable AJCC stage III or IV melanoma, prior combination 
biochemotherapy for cancer, unstable brain metastasis or spinal cord compression 
(<3 months off steroids), and history of another primary malignancy within 5 years prior to 
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start of study treatment (except for adequately treated basal or squamous cell skin cancer or 
cancer of the cervix in situ). 
Study design 
Patients were randomized 1:1 to selumetinib (100 mg free-base solution, twice daily in 28-
day cycles) or TMZ (200 mg/m2/day for 5 days, followed by 23 days off treatment). 
Assessment by RECIST criteria was performed at weeks 6 and 12, and then every 8 weeks 
for progression-free survival (PFS). Local center tumor assessment was used for the primary 
analysis, with conclusions validated by an independent central review of scans/images. 
Patients could continue study treatment until objective disease progression (defined by local 
investigator) and were then followed for survival. Patients with progressive disease (PD), as 
assessed by the investigator in the TMZ group, were permitted to crossover to selumetinib.  
Data cut-off was 28 September 2007 for PFS and objective tumor response. All other 
analyses, including time-to-death (TTD) used a date of 20 June 2008.  
Study objectives 
The primary objective was to compare the efficacy of selumetinib versus TMZ in patients 
with unresectable stage III or IV malignant melanoma. The primary outcome was PFS. 
Secondary outcomes were TTD, objective response rate (ORR) and duration of response.  
PFS, defined as the interval between the date of randomization and the first date of objective 
disease progression (RECIST 1.0) or death due to any cause, was to be analyzed following 
approximately 126 progression events. Non-progressing patients were censored at last 
objective tumor assessment. 
TTD was calculated from randomization until death due to any cause; surviving patients 
were censored at last date known to be alive, or withdrawal of consent. 
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Best objective response (OR) (complete response [CR], partial response [PR], SD ≥6 
weeks) or PD was calculated as the best response, using RECIST 1.0, recorded from date 
of randomization.  
Secondary objectives included assessment of safety, tolerability, and efficacy of selumetinib 
versus TMZ with respect to BRAF or NRAS mutation status. 
Exploratory analyses included assessment of the treatment effect in the following subgroups; 
disease stage (Stage III v Stage IV), uveal melanoma v non-uveal, mucosal melanoma v 
non-mucosal, and BRAF and NRAS mutation status. 
Assessment of safety 
Adverse events (AEs), serious AEs (SAEs), clinical laboratory evaluations, vital signs and 
electrocardiograms were collected from provision of informed consent until 30 days after 
discontinuation of study treatment. AEs were collected using Common Terminology Criteria 
for Adverse Events (CTCAE) Version 3. 
Determination of BRAF and NRAS mutation status  
Pathology review confirmed the presence of tumor; no enrichment by macro-dissection was 
performed prior to DNA extraction, given the high sensitivity of the allele-specific polymerase 
chain reaction (PCR)-based method ARMS™ (Amplification Refractory Mutation System). 
The methods used for mutation detection including sequences of primers and probes for 
detection of BRAF and NRAS mutations have been previously described (23). The allele-
specific PCR detects BRAF V600E as well as V600K and V600D (1799T>A), the allele-
specific PCR for NRAS detects NRAS Q61K mutation (C181A) and the Q61R mutation 
(A182G). Mutation testing was carried out centrally within the AstraZeneca tumor genetics 
research laboratory.  
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In brief, genomic DNA was extracted from thin sections totaling 40 μm by digestion in 
proteinase K for 48 h, boiling in 5% chelex, phase-extracting in chloroform, ethanol-
precipitating and resuspending in 100 μl water. PCR was performed as described previously, 
utilizing cell line admixtures containing the mutation of interests to act as positive controls 
(23). 
A mutation-positive result was only accepted if it was present in two independent PCRs 
generated from the same DNA sample. Normal genomic DNA was used as a negative 
control. Results were not designated positive unless the mutation was detected at a level 
above the non-specific background noise. This was done in order to control for false-positive 
results. A ‘negative’ result from an assay could represent no mutation present; if there was  
insufficient DNA extracted from the sample to identify the presence of the mutation it was 
designated a fail. 
Determination of GNAQ mutation status  
GNAQ analysis was performed in uveal melanoma tumors only. Codon 209 was analyzed by 
ARMS™ and direct sequencing. The same forward primer was used for both sequencing 
and ARMS™: 5’-ACTGTAAAACGACGGCCAGTTTTTCCCTAAGTTTGTAAGTAGTGCT-3’. 
Reverse primers were used as follows: GNAQ sequencing reverse, 5’-
ACCAGGAAACAGCTATGACCGTCTGACTCCACGAGAACTTGAT-3’; GNAQ 209P 
ARMS™ reverse, 5’-AGTGTATCCATTZTCTTCTCTCTGACCTTP-3’; GNAQ 209L ARMS™ 
reverse, 5’-AGTGTATCCATTZTCTTCTCTCTGACCTTE-3’ (L=LNA [locked nucleic acid] 
modified C, P=LNA G, Z=LNA T). 
Statistical and analytical methods 
A sample size of 182 patients (91 per arm) was required to provide adequate power for 
comparison of PFS between the two treatment groups both in the overall population and in 
the BRAF mutant subpopulation (24). Patients with BRAF mutant tumors (assumed to be 
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60% of the total) (9) were hypothesized to show a greater response to selumetinib than 
those with wild-type tumors. The target PFS hazard ratio (HR) in the BRAF mutant subgroup 
was 0.67 (and was to be tested as a secondary endpoint at the one-sided significance level 
of 20%).  
To maintain statistical power for the overall population, the target HR on which the study was 
powered was 0.74 for PFS (i.e., a 35% delay in median time to progression assuming 
exponential distribution). This assumed that the BRAF wild-type subpopulation contained 
NRAS mutant patients (approximately 30%), who might derive clinical benefit. 
This study was designed to have 80% power to detect a true PFS HR of 0.74 in the overall 
population at the one-sided 20% significance level, and required approximately 126 
progression events. The trial was designed as a randomized screening trial to quantify the 
level of risk entailed for further development, and as such the Type I and Type II errors were 
adjusted to be less constrained, so that the targeted treatment benefit may be appropriate 
while the sample size remains reasonable (25) (as discussed by Rubinstein LV et al 2005).   
PFS and TTD were analyzed using a Cox Proportional Hazards model allowing for the effect 
of treatment and fitting for the following baseline covariates: BRAF mutation status (positive 
v negative v unknown), WHO performance status (0 v 1 or 2), tumor type (non-uveal 
[cutaneous, mucosal, unknown] v uveal) and level of lactate dehydrogenase (<2 x ULN v ≥2 
x ULN) at baseline. These covariates were thought to be potentially prognostic and thus the 
impact of these covariates is adjusted for in the statistical analyses in order to improve the 
precision of the estimated treatment effect as well as compensating for any lack of balance 
between groups for these baseline covariates. The model included these effects regardless 
of whether the inclusion of effects significantly improved the fit of the model. These analyses 
were pre-specified in the Statistical Analysis Plan. Tumor stage (III vs. IV) was pre-specified 
as a covariate but not included in the model as only six patients had an unresectable AJCC 
stage III tumor. 
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Intention-to-treat (ITT) analysis was used for all efficacy analyses. The ITT population 
included all randomized patients and compared the treatment groups on the basis of 
randomized treatment, regardless of the treatment actually received. The evaluable-for-
safety population was a subset of the ITT population that included all patients who received 
≥1 dose of study treatment and was used for summaries of the safety data. 
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Results 
Demographics and other patient characteristics 
Two hundred and thirty-nine patients were enrolled, of whom 200 were randomized: 104 to 
selumetinib and 96 to TMZ (Fig. 1). Of these patients, 99 and 95 received selumetinib and 
TMZ, respectively. Ninety-six and 92 patients, respectively, discontinued assigned treatment 
with selumetinib or TMZ. Three patients in each arm were continuing assigned treatment at 
the time of data cut-off. Fifty-nine patients in the TMZ arm switched to selumetinib. In total, 
158 randomized patients (79.0%) had their BRAF and NRAS mutation status confirmed. 
BRAF mutant tumors were identified in 73/158 patients (46.2%) (V600E – 66, V600K – 5, 
K601E – 1, K581S – 1); 28/158 patients’ tumors (17.7%) were NRAS mutated (Q61K – 15, 
Q61R – 12, G13R – 1). No tumors were both BRAF and NRAS mutated; therefore, 101/158 
patients’ tumors (63.9%) were either BRAF mutant or NRAS mutant. Of the 42 patients 
without confirmed mutation status, 24 did not have samples to analyze and 18 had no result 
due to assay failure.  
The study population was representative of the advanced melanoma clinical population in 
terms of baseline and demographic characteristics; however, there were some imbalances 
between the treatment arms (Table 1). There was a higher percentage of women in the 
selumetinib group (47.1%) than in the TMZ group (32.3%). In addition, more patients were 
BRAF mutant in the selumetinib group (43.3%) than in the TMZ group (29.2%), and more 
patients in the selumetinib group had WHO performance status 1 or 2 compared with those 
receiving TMZ (33.7% and 26.1%, respectively).  
In the BRAF and NRAS mutant subpopulation, more patients had WHO performance status 
1 or 2 in the selumetinib group (38.2%) than in the TMZ group (23.9%). Furthermore, more 
BRAF or NRAS mutant patients in the selumetinib group (12.7%) had lactate dehydrogenase 
levels ≥2 x ULN compared with those in the TMZ group (8.7%). The analyses adjusted for 
these factors. 
 American Association for Cancer Research Copyright © 2011 
 on January 5, 2012clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 2, 2011; DOI:10.1158/1078-0432.CCR-11-1491
  14
Twenty (10%) patients in the study had uveal melanoma, with 15 evaluable for BRAF/NRAS 
mutations; no mutations in BRAF or NRAS were detected. Twelve patients with uveal 
melanoma had tumors with sufficient material evaluable for GNAQ mutation: four tumors 
were GNAQ mutated (three GNAQ 209P, one GNAQ 209L), eight tumors were GNAQ wild-
type. 
Efficacy 
Progression-free survival based on investigator assessed RECIST data 
The PFS analysis was performed after 151 progression events. No difference in PFS was 
observed between selumetinib and TMZ (HR 1.07; 80% confidence interval [CI]: 0.86–1.32; 
1-sided p=0.650; 2-sided p=0.699) (Fig. 2A). In pre-specified analyses, PFS was consistent 
across subgroups (data not shown) except for patients with uveal melanoma (HR 0.70; 80% 
CI: 0.35–1.42) but no significant difference could be concluded for patients with uveal 
melanoma due to the small number of patients (16 events/20 patients) and wide CI. Overall, 
79 (76%) patients in the selumetinib group and 72 (75%) patients randomized to TMZ had 
objective disease progression or had died at the data cut-off point, with median time to event 
of 78 and 80 days, respectively.  
Due to open-label nature of the study an independent central review was incorporated to 
assess consistency and ensure that conclusions were robust. Discordance between the 
disease status assessment in local and central review was noted, with local review more 
favorable for selumetinib (Supplemental Table 1) (26). In 20% of cases, the discrepancy was 
due to different assessments of percentage change of target lesions alone and 31% were 
due to the identification of one or more new lesions alone (Supplemental Table 2) either by 
the local review or by central review. This discordance did not change the conclusions of this 
study. 
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Time to death 
The final analysis of TTD was performed after 130 deaths had occurred. The median TTD 
was 284 and 369 days for selumetinib and TMZ groups, respectively (HR: 1.351; 80% CI: 
1.07–1.71; 95% CI: 0.95–1.93; 1-sided p=0.950; 2-sided p=0.099) (Table 2), suggesting 
improved but not statistically significant TTD for TMZ compared with selumetinib in the 
overall population (Fig. 2B). A higher proportion of patients randomized to TMZ received 
selumetinib following disease progression (61%) compared with those who received TMZ or 
dacarbazine following progression on selumetinib (≥24%). The frequency of crossover from 
selumetinib to TMZ may be an underestimation as this information was not mandatorily 
gathered as part of the study protocol.  
Objective response rate based on investigator assessed RECIST data 
Statistical comparisons of ORR and duration of response were not formally performed due to 
the low number of responses. The number of patients with confirmed PR was 5.8% (6/104) 
for patients in the selumetinib group and 9.4% (9/96) in the TMZ group (Table 3). No CRs 
were observed in either group. Forty-eight (46.2%) patients in the selumetinib group had SD 
of ≥6 weeks’ duration compared with 36 (37.5%) in the TMZ group. At the time of the overall 
survival analysis, two new PRs were observed in patients with wild-type tumors randomized 
to TMZ and one TMZ patient with a previous PR became a CR. Of the 11 responders in the 
TMZ group, the duration of response ranged from 94 to ≥420 days (three patients were still 
responding at time of data cut-off). In the selumetinib group the duration of response ranged 
from 130 to 358 days (all patients had progressed). 
Efficacy in patients with BRAF or NRAS mutations 
There were no significant differences in PFS between the two treatment groups in the BRAF-
mutant (Fig. 2C) and BRAF- or NRAS-mutant subsets (not shown). Among patients with 
BRAF mutation, objective tumor response was observed in 11.1% (5/45) of patients 
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receiving selumetinib and 10.7% (3/28) of the TMZ group. Similarly, in the patient 
subpopulation with BRAF or NRAS mutations, the objective tumor responses were 9.1% 
(5/55) and 8.7% (4/46) in the selumetinib and TMZ groups, respectively (Table 3). Of the six 
selumetinib responders, five were BRAF mutant compared with three of the nine TMZ 
responders. As with the overall population, BRAF mutant patients randomized to TMZ had 
improved TTD compared with those randomized to selumetinib (Fig. 2D).  
Efficacy in patients who switched treatment  
As of 28 September 2007, 51 patients randomized initially to TMZ had switched to 
selumetinib; 46 (90.2%) switched following objective disease progression and five patients 
switched incorrectly (before objective disease progression as assessed by site RECIST 
data). Three switches were due to an incorrect assessment of objective disease progression 
and the other two resulted from clinical progression alone (the latter two patients went on to 
progress according to RECIST 28 days and 64 days after switching to AZD6244; the first 
patient had new lesions and the second died).  
As of 20 June 2008, 59 of the 96 patients randomized to TMZ (61%) had switched to 
selumetinib (54/59 patients after objective disease progression). No further patients had 
incorrectly switched prior to disease progression. One patient (2%) had PR, 25 (46%) had 
PD and 8 (15%) were not evaluable. Two patients who switched exhibited PR while 
receiving selumetinib; however, one of these switched prior to objective disease progression 
on TMZ and so is counted as a response to TMZ. The patient with confirmed PR on 
selumetinib following progression to TMZ was BRAF mutant.  
Change in tumor size  
Exploratory plots were produced to assess the change from baseline in tumor size by week 
6 and best overall change at time of primary analysis (Supplemental Fig.1). Overall there 
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was little difference between the two treatment groups for change in tumor size, either at 
week 6 or for best overall change. 
Safety 
Adverse events 
Most AEs reported in this study were CTCAE Grade 1 or 2 and were manageable with drug 
holiday or standard supportive therapy (Table 4). Fewer patients in the TMZ group had 
treatment-related AEs, AEs ≥ Grade 3, SAEs or AEs leading to discontinuation compared 
with the selumetinib group. The most frequent SAEs in the selumetinib group were diarrhea 
(n=3), vomiting (n=3) and infections (n=3). Small intestinal obstruction (n=2) and confusional 
state (n=2) were the most frequent SAEs in the TMZ group. Three deaths were reported in 
patients receiving selumetinib; one death due to unknown cause occurred in the absence of 
tumor progression, one patient died of metastases to meninges (disease progression) and 
one patient experienced cardiorespiratory arrest that was attributed to selumetinib by the 
investigator. A further selumetinib-randomized patient died outside of the 30-day follow-up 
reporting period as a result of myocarditis.  
The most commonly reported AEs were dermatitis acneiform (59.6%), diarrhea (56.6%) and 
nausea (50.5%) in the selumetinib group, and nausea (64.2%), constipation (47.4%) and 
vomiting (44.2%) in the TMZ group (Table 4).  
Laboratory evaluation 
Deterioration in hematology parameters of at least two grades from baseline was observed 
in fewer patients treated with selumetinib than with TMZ; leukocytes (1.0% v 8.5%), 
lymphocytes (6.1% v 14%), neutrophils (2.0% v 7.5%) and platelets (1.0% v 11.7%).  
A greater proportion of patients receiving selumetinib demonstrated deterioration of at least 
two grades from baseline in clinical chemistry parameters than with TMZ: alanine 
 American Association for Cancer Research Copyright © 2011 
 on January 5, 2012clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 2, 2011; DOI:10.1158/1078-0432.CCR-11-1491
  18
aminotransferase (13.1% v 3.2%), aspartate aminotransferase (11.8% v 2.4%) and albumin 
(16.3% v 1.1%). Bilirubin levels remained normal in both treatment groups.  
A slight increase in calcium-phosphate product level was observed in the selumetinib group, 
with six patients reporting levels above the pre-defined cut-off (4.5 mmol/L). One of these 
patients had an SAE (Grade 3) of hyperphosphatemia. 
Small increases in mean systolic (7.4 mmHg) and diastolic (5.3 mmHg) blood pressure, 
without a corresponding change in heart rate, were observed in the selumetinib group by 
week 8. Hypertension was reported as an AE by eight (8.1%) patients in the selumetinib 
group and two (2.1%) in the TMZ group. 
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Discussion  
Advanced melanoma represents one of the most treatment-refractory malignancies. Despite 
decades of research, worldwide consensus on a standard first-line treatment has yet to be 
established. While dacarbazine and TMZ are used for first-line chemotherapy of advanced 
melanoma, patient response to these agents is low (22, 27). The present study investigated 
the role of the oral MEK1/2 inhibitor selumetinib as monotherapy for patients with 
unresectable stage III/IV melanoma. No significant difference was seen in the primary 
endpoint of PFS between the two treatment arms for either the overall population or the 
subpopulations of patients with BRAF or BRAF/NRAS mutant tumors. Although some 
imbalances were seen between treatment groups in baseline covariates, the statistical 
analyses adjusted for the impact of these factors. Disease control (5.8% PR; 46.2% SD) with 
selumetinib monotherapy was observed. Because of the open-label nature of this trial, an 
independent central review of tumor assessment was incorporated to ensure consistency. 
However, as stated in the protocol, the primary efficacy analysis was based on the 
investigator-assessed RECIST data as this was considered to be more reflective of clinical 
practice and the central review was not carried out in real time. As has been reported for 
other studies (28), differences between local and central review were noted but this did not 
alter the conclusions of the primary analyses. 
Tumor responses to selumetinib monotherapy have been observed in patients with 
melanoma and other solid tumors, suggesting anti-tumor activity with this MEK1/2 inhibitor. 
Cell lines expressing BRAF or RAS mutations (including melanoma cell lines) have 
increased sensitivity to selumetinib (29). This is particularly relevant to melanoma since 
recent estimates suggest that activating mutations of BRAF and NRAS are found in 41% and 
18% of melanomas, respectively (11). Although the present study did not test for mutation 
status prospectively, 79% of patients had mutation status confirmed retrospectively. 
Retrospective mutation testing could be considered a limitation of this study given the 
imbalance seen between treatment arms. However, the rationale for pre-specified 
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retrospective testing was 2-fold: firstly, implementing prospective testing of patients would 
require central testing in a time frame that might withhold treatment from patients for a 
prolonged period of time, and secondly the primary objective was to assess efficacy in the 
overall population, and so making patients wait for a mutation test before starting treatment, 
when the result would not exclude them from entering the trial, was felt not to be in the 
patients’ best interests.  
The observed BRAF mutation rate of 46.2% is lower than had been expected when planning 
this study but similar to recent reports (11, 30, 31). Of note in our study, five of the six 
patients showing PR with selumetinib had tumors that were BRAF mutant. This finding 
raises the possibility that BRAF mutation may be an important, but not exclusive, 
requirement for response to selumetinib. Data from other compounds in development have 
shown that patients with BRAF mutant tumors can show a high response rate to MEK or 
BRAF inhibition (12, 13, 32-34). For example, a phase I trial of the MEK inhibitor 
GSK112012 demonstrated disease control in eight of eleven patients with BRAF mutant 
melanoma (32). This suggests that additional genetic markers may be necessary for a cell to 
respond to selumetinib monotherapy. In line with this hypothesis, a transcriptional profile 
associated with activation of MEK and sensitivity to selumetinib pre-clinically has recently 
been identified, although this may not be predictive of clinical benefit (35). Testing performed 
on samples from this study showed no correlation between this transcription profile and 
clinical response (AstraZeneca, data on file). 
The clinical challenge is, therefore, to find ways of optimizing the efficacy of selumetinib, for 
example through combination with other targeted agents or chemotherapy. In preclinical 
models, selumetinib in combination with docetaxel, irinotecan, gemcitabine or TMZ was 
shown to have enhanced anti-tumor efficacy compared with single-agent treatment (36). 
Preliminary clinical results from a phase I trial of selumetinib in combination with either 
dacarbazine, docetaxel or temsirolimus have demonstrated objective response in five out of 
nine patients with BRAF mutation-positive tumors (37). Selumetinib is currently being 
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investigated for advanced melanoma in combination with dacarbazine for patients with 
prospectively determined BRAF mutant tumors (NCT00936221).  
Possible theories for the non-significant improved survival of patients initially assigned to 
TMZ versus selumetinib (other than a chance finding) were examined, but no clear 
explanation was found. Firstly, selumetinib might have had a detrimental effect in relation to 
survival, but no differences in other efficacy endpoints (PFS, ORR, change in tumor size) 
and safety data did not suggest this, either in this trial or a separate comparative phase II 
trial measuring TTD (38). Secondly, an imbalance in prognostic factors might have 
contributed to this outcome, but this is unlikely since imbalances in a range of prognostic 
factors (lactate dehydrogenase, WHO performance status, BRAF mutation status and tumor 
type) had already been accounted for in the TTD analysis. Thirdly, an imbalance in the 
number of patients that crossed over from TMZ to selumetinib, or vice versa, (61% TMZ arm 
versus ~25% selumetinib arm) could have affected the outcome; for example, the possibility 
that the sequential administration of two equally active agents prolonged survival 
(selumetinib has activity that is preliminarily in the range of TMZ, and PFS curves are not 
dissimilar). However, the relative activity of these agents in the first- and second-line setting 
is unknown. Additionally, the relative activity of non-study treatments that non-crossover 
patients went on to receive after TMZ and selumetinib is unknown. 
To be representative of the general melanoma population, patients with uveal melanoma 
were included in this study. It was felt that these patients have the potential to benefit from 
MEK inhibition because they may carry somatic mutations such as GNAQ and GNA11 (39). 
Analysis of efficacy in these patients was an exploratory endpoint that did not translate into a 
significant clinical benefit in this trial. However, based on anecdotal evidence from this and a 
Phase I study (19), a Phase II study of selumetinib in patients with uveal melanoma has 
been initiated, NCT01143402. 
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Selumetinib was generally well tolerated; the reported AEs were consistent with prior reports 
(19, 40), and no new clinically significant safety issues were identified in the present study. 
There was a higher reported incidence of dermatitis acneiform, diarrhea and peripheral and 
periorbital edema with selumetinib than with TMZ. Nausea, vomiting, constipation, dyspnea 
and fatigue were more commonly reported in the TMZ group than in the selumetinib group, 
which is consistent with the prescribing information for TMZ. Hematological toxicities were 
not an issue with selumetinib.  
Dermatological toxicities with selumetinib resemble those observed with epidermal growth 
factor receptor inhibitors (41) in their clinical presentation (dermatitis acneiform, xerosis 
cutis, paronychia) (40). These skin toxicities can be ameliorated by topical corticosteroid 
and/or antibacterial therapy (40, 42) and responded to dose interruptions or discontinuation 
of therapy. In the present study, selumetinib-associated dermatologic conditions were 
manageable; only one patient discontinued study treatment due to dermatitis acneiform. It 
has been suggested that there may be a link between rash and the signal transduction 
pathway. An exploratory (unplanned) analysis of rash (maximum grade on treatment) and 
efficacy (maximum change in tumor size) found no relationship (AstraZeneca, data on file). 
The toxicity profile of selumetinib in this trial therefore appears to be manageable. However, 
it is possible that the acceptable tolerability of selumetinib may be a consequence of under-
dosing in this study and could, therefore, explain the low number of responses observed. 
During development of selumetinib the dose-limiting toxicities and maximum tolerated dose 
were based on the frequency of rash. It is possible that in the subsequent development of 
newer MEK inhibitors, lessons were learnt from these early trials of selumetinib and other 
MEK inhibitors, and the management of rash that results from administration of this type of 
drug is now more effective. For example, in a phase I trial of the MEK inhibitor GSK1120212 
which had disease control rate of 73%, the frequency of rash was 77% (43). However, the 
frequency of grade 3 rash was lower than that seen in our study, suggesting that although 
the incidence of rash may be higher overall it could be better controlled with optimal 
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supportive care. It is therefore possible that the dose of selumetinib used in this phase II 
study was overcautious with regard to toxicity and that the maximal dosage range was not 
explored in full. It should therefore be noted that ongoing and future trials of selumetinib will 
use a 75 mg hydrazine-sulfate tablet formulation which demonstrates statistically 
significantly higher plasma exposure as well as oral bioavailability 197% that of the 100 mg 
free-base suspension used in this study (44). 
In conclusion, the oral MEK1/2 inhibitor selumetinib showed modest activity with no 
significant difference in PFS compared with TMZ in chemotherapy-naïve, patients with 
advanced melanoma unselected for BRAF mutations. The objective tumor responses 
observed were comparable in both the overall and BRAF and NRAS mutant populations; 
however, five out of six selumetinib responders had BRAF mutant tumors. Further 
development of selumetinib in this disease will therefore focus on combination with other 
agents and upon the selection of patients for therapy, using BRAF mutation status. 
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Table 1. Patient demographics and baseline characteristics 
 Treatment group 
 Selumetinib (n = 104) 
n (%) 
Temozolomide (n = 96) 
n (%) 
Sex    
Male  55 (52.9) 65 (67.7) 
Female  49 (47.1) 31 (32.3) 
Age, years    
Mean (range)  57.1 (20-84) 57.0 (28-84) 
Racial origin   
Caucasian  99 (95.2) 91 (94.8) 
Non-Caucasiana 3 (2.9) 3 (3.0) 
Unknown  2 (1.9) 2 (2.1) 
WHO performance status 
0 Normal activity 
1 Restricted activity 
2 In bed ≤ 50% of the time 
Unknown 
 
67 (64.4) 
34 (32.7) 
1 (1.0) 
2 (1.9) 
 
71 (74.0) 
23 (24.0) 
2 (2.1) 
0 (0) 
AJCC staging 
Stage III 
Stage IV 
M1a/b 
M1c 
Unknown M status 
Unknown stage 
 
3 (2.9) 
99 (95.2) 
40 (38.5) 
58 (55.8) 
1 (1) 
2 (1.9) 
 
3 (3.1) 
92 (95.8) 
36 (37.5) 
54 (56.3) 
2 (2.1) 
1 (1.0) 
Lactate dehydrogenase level at baselinee 
<2 x ULN 
≥2 x ULN 
Unknown 
 
79 (76.0) 
17 (16.3) 
8 (7.7) 
 
79 (82.3) 
15 (15.6) 
2 (2.1) 
Tumor type   
Cutaneous 75 (72.1) 72 (75.0) 
Uveal 7 (6.7) 13 (13.5) 
Mucosal 6 (5.8) 0 (0.0) 
Unknown primary tumor 16 (15.4) 11 (11.5) 
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Mutation status   
BRAF positive 45 (43.3) 28 (29.2) 
NRAS positive 10 (9.6) 18 (18.8) 
Wild-type for both 29 (27.9) 28 (29.2) 
Unknownb 20 (19.2) 22 (22.9) 
a This group comprised Black, Hispanic and Mediterranean patients. 
b This group comprised those patients where there was no result for both BRAF and NRAS mutation 
status or one of the mutation assays failed. 
Abbreviation: ULN, upper limit of normal. 
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Table 2. Summary of time-to-death analysis for selumetinib v temozolomide in the overall population and in BRAF and NRAS mutant patients 
 Number of 
patients 
Number of 
deaths (%) 
Median time to 
event (days) 
Hazard ratioa Confidence interval p-value 
2-sided 80% 2-sided 95% 1-sidedb 2-sided
Overall populationc 
Selumetinib 104 73 (70.2) 284 
1.351 1.07, 1.71 0.95, 1.93 0.950 0.099 
Temozolomide 96 57 (59.4) 369 
BRAF-mutant subpopulationd 
Selumetinib 45 34 (75.6) 284 
1.654 1.12, 2.45 0.91, 3.02 0.949 0.102 
Temozolomide 28 16 (57.1) 369 
BRAF- and NRAS-mutant subpopulationd 
Selumetinib 55 42 (76.4) 275 
1.621 1.18, 2.23 0.99, 2.65 0.973 0.053 
Temozolomide 46 27 (58.7) 383 
a Hazard ratio <1 indicated a benefit for selumetinib. 
b The 1-sided p-value indicated whether selumetinib was associated with longer time-to-death than temozolomide. 
c Analyzed using Cox Proportional Hazards model adjusted for: lactate dehydrogenase (LDH), BRAF mutational status, WHO performance status and primary 
tumor type. 
d Analyzed using the Cox Proportional Hazards model adjusted for: LDH and WHO performance status. 
Abbreviations: LDH, lactate dehydrogenase; WHO, World Health Organization. 
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Table 3. Objective tumor response for selumetinib and temozolomide 
Response status Objective tumor response 
Treatment group 
Selumetinib 
n (%) 
Temozolomide 
n (%) 
Overall population n = 104 n = 96 
Responsea Complete response 0 0 
 Partial response 6 (5.8) 9 (9.4) 
 Total 6 (5.8) 9 (9.4) 
Non-response Stable disease ≥6 weeks 48 (46.2) 36 (37.5) 
 Progressive disease 40 (38.5) 43 (44.8) 
 Non-evaluable 10 (9.6) 8 (8.3) 
 Total 98 (94.2) 87 (90.6) 
BRAF mutant subpopulation n = 45 n = 28 
Responsea Complete response 0 0 
 Partial response 5 (11.1) 3 (10.7) 
 Total 5 (11.1) 3 (10.7) 
Non-response Stable disease ≥6 weeks 18 (40.0) 12 (42.9) 
 Progressive disease 17 (37.8) 11 (39.3) 
 Non-evaluable 5 (11.1) 2 (7.1) 
 Total 40 (88.9) 25 (89.3) 
BRAF and NRAS mutant subpopulation n = 55 n = 46 
Responsea Complete response 0 0 
 Partial response 5 (9.1) 4 (8.7) 
 Total 5 (9.1) 4 (8.7) 
Non-response Stable disease ≥6 weeks 23 (41.8) 21 (45.7) 
 Progressive disease 21 (38.2) 19 (41.3) 
 Non-evaluable 6 (10.9) 2 (4.3) 
 Total 50 (90.9) 42 (91.3) 
a An objective response included patients with either a confirmed complete response or partial 
response according to Response Evaluation Criteria in Solid Tumors Version 1.0. 
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Table 4. Most frequent all-causality adverse events (occurring in at least 15% of patients in 
each group), serious adverse events and discontinuations due to any adverse events 
 Number (%) of patients 
 
Selumetinib 
n = 99 
Temozolomide  
n = 95 
Preferred term AE AE ≥ Grade 3 AE AE ≥ Grade 3 
AE 99 (100.0) 57 (57.6) 92 (96.8) 36 (37.9) 
Dermatitis acneiform 59 (59.6) 12 (12.1) 3 (3.2) 0 (0.0) 
Diarrhea 56 (56.6) 4 (4.0) 20 (21.1) 0 (0.0) 
Nausea 50 (50.5) 3 (3.0) 61 (64.2) 3 (3.2) 
Peripheral edema 40 (40.4) 1 (1.0) 6 (6.3) 3 (3.2) 
Fatigue 29 (29.3) 3 (3.0) 40 (42.1) 4 (4.2) 
Vomiting 28 (28.3) 1 (1.0) 42 (44.2) 6 (6.3) 
Headache 21 (21.2) 3 (3.0) 23 (24.2) 2 (2.1) 
Pyrexia 16 (16.2) 1 (1.0) 10 (10.5) 0 (0.0) 
Constipation 12 (12.1) 0 (0.0) 45 (47.4) 1 (1.1) 
Serious AEs 32 (32.3) 16 (16.8) 
Discontinuations due to AEs 10 (10.1) 2 (2.1) 
 
This table includes adverse events with an onset date between the date of the first dose and 30 days 
following the date of the last dose of study treatment (unless the patient switched to selumetinib 
earlier than 30 days following discontinuation of temozolomide). 
Abbreviation: AE, adverse event. 
 
  
 American Association for Cancer Research Copyright © 2011 
 on January 5, 2012clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 2, 2011; DOI:10.1158/1078-0432.CCR-11-1491
  37
Table legends 
Table 1. Patient demographics and baseline characteristics 
Table 2. Summary of time-to-death analysis for selumetinib v temozolomide in the overall 
population and in BRAF and NRAS mutant patients 
Table 3. Objective tumor response for selumetinib and temozolomide 
Table 4. Most frequent all-causality adverse events (occurring in at least 15% of patients in 
each group), serious adverse events and discontinuations due to any adverse events 
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Figure legends 
Fig. 1. Patient disposition. 
Fig. 2. Comparison of progression-free survival, (A) and (C), and of time-to-death, (B) and 
(D), between selumetinib and temozolomide in the overall population (A) and (C) and BRAF 
mutant patients, (B) and (D). 
Abbreviations: HR, hazard ratio; CI, confidence interval 
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Figures 
Fig. 1. Patient disposition 
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Fig. 2. Comparison of progression-free survival, (A) and (C), and of time-to-death, (B) and 
(D), between selumetinib and temozolomide in the overall population (A) and (C) and BRAF 
mutant patients, (B) and (D). 
A) Kaplan–Meier comparison of progression-free survival between selumetinib and 
temozolomide in the overall population (intent-to-treat population). 
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(B) Kaplan–Meier comparison of time-to-death between selumetinib and temozolomide in 
the overall population (intent-to-treat population). 
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(C) Kaplan–Meier comparison of progression-free survival between selumetinib and 
temozolomide in the BRAF mutant subpopulation (intent-to-treat population). 
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(D) Kaplan–Meier comparison of time-to-death between selumetinib and temozolomide in 
the BRAF mutant subpopulation (intent-to-treat population). 
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Table 1.
Selumetinib (n = 104) Temozolomide (n = 96)
n (%) n (%)
Sex 
Male 55 (52.9) 65 (67.7)
Female 49 (47.1) 31 (32.3)
Age, years 
Mean (range) 57.1 (20-84) 57.0 (28-84)
Racial origin
Caucasian 99 (95.2) 91 (94.8)
Non-Caucasian
a 3 (2.9) 3 (3.0)
Unknown 2 (1.9) 2 (2.1)
WHO performance status
0 Normal activity 67 (64.4) 71 (74.0)
1 Restricted activity 34 (32.7) 23 (24.0)
2 In bed ≤ 50% of the time 1 (1.0) 2 (2.1)
Unknown 2 (1.9) 0 (0)
AJCC staging
Stage III 3 (2.9) 3 (3.1)
Stage IV 99 (95.2) 92 (95.8)
M1a/b 40 (38.5) 36 (37.5)
M1c 58 (55.8) 54 (56.3)
Unknown M status 1 (1) 2 (2.1)
Unknown stage 2 (1.9) 1 (1.0)
Lactate dehydrogenase level at baseline
e
< 2 x ULN 79 (76.0) 79 (82.3)
≥ 2 x ULN 17 (16.3) 15 (15.6)
Unknown 8 (7.7) 2 (2.1)
Tumor type
Cutaneous 75 (72.1) 72 (75.0)
Uveal 7 (6.7) 13 (13.5)
Mucosal 6 (5.8) 0 (0.0)
Unknown primary tumor 16 (15.4) 11 (11.5)
Mutation status
BRAF positive 45 (43.3) 28 (29.2)
NRAS positive 10 (9.6) 18 (18.8)
Wild-type for both 29 (27.9) 28 (29.2)
Unknown
b 20 (19.2) 22 (22.9)
a 
This group comprised Black, Hispanic and Mediterranean patients.
b 
This group comprised those patients where there was no result for both BRAF  and NRAS  mutation status or one of the mutation assays failed.
Abbreviation: ULN, upper limit of normal.
Treatment group
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Table 2. 
p-value
(1-sided)
b
Selumetinib 104 73 (70.2) 284
Temozolomide 96 57 (59.4) 369
Selumetinib 45 34 (75.6) 284
Temozolomide 28 16 (57.1) 369
Selumetinib 55 42 (76.4) 275
Temozolomide 46 27 (58.7) 383
a 
Hazard ratio < 1 indicated a benefit for selumetinib.
b 
The 1-sided p-value indicated whether selumetinib was associated with longer time-to-death than temozolomide.
c 
Analyzed using Cox Proportional Hazards model adjusted for: lactate dehydrogenase (LDH), BRAF mutational status, WHO performance status and primary tumor type.
d 
Analyzed using the Cox Proportional Hazards model adjusted for: LDH and WHO performance status.
BRAF  and NRAS  mutant subpopulation
d
1.621 1.18, 2.23 0.973
Overall population
c
1.351 1.07, 1.71 0.95
BRAF  mutant subpopulation
d
1.654 1.12, 2.45 0.949
Number of 
patients
Number of 
deaths (%)
Median time to 
event (days) Hazard ratio
a
2-sided 80% CI
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Table 3. 
Selumetinib Temozolomide
n (%) n (%)
n = 104 n = 96
Response
a
Complete 
response 0 0
Partial response 6 (5.8) 9 (9.4)
Total 6 (5.8) 9 (9.4)
Non-response
Stable disease ≥ 
6 weeks 48 (46.2) 36 (37.5)
Progressive 
disease 40 (38.5) 43 (44.8)
Non-evaluable 10 (9.6) 8 (8.3)
Total 98 (94.2) 87 (90.6)
n = 45 n = 28
Response
a
Complete 
response 0 0
Partial response 5 (11.1) 3 (10.7)
Total 5 (11.1) 3 (10.7)
Non-response
Stable disease ≥ 
6 weeks 18 (40.0) 12 (42.9)
Progressive 
disease 17 (37.8) 11 (39.3)
Non-evaluable 5 (11.1) 2 (7.1)
Total 40 (88.9) 25 (89.3)
n = 55 n = 46
Response
a
Complete 
response 0 0
Partial response 5 (9.1) 4 (8.7)
Total 5 (9.1) 4 (8.7)
Non-response
Stable disease ≥ 
6 weeks 23 (41.8) 21 (45.7)
Progressive 
disease 21 (38.2) 19 (41.3)
Non-evaluable 6 (10.9) 2 (4.3)
Total 50 (90.9) 42 (91.3)
a 
An objective response included patients with either a confirmed complete response or partial response according to RECIST.
Response status
Objective tumor 
response
Treatment group
Overall population
BRAF mutant subpopulation
BRAF  and NRAS  mutant 
subpopulation
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Table 4. 
Preferred term AE AE ≥ Grade 3 AE AE ≥ Grade 3
AE 99 (100.0) 57 (57.6) 92 (96.8) 36 (37.9)
Dermatitis 
acneiform 59 (59.6) 12 (12.1) 3 (3.2) 0 (0.0)
Diarrhea 56 (56.6) 4 (4.0) 20 (21.1) 0 (0.0)
Nausea 50 (50.5) 3 (3.0) 61 (64.2) 3 (3.2)
Peripheral edema 40 (40.4) 1 (1.0) 6 (6.3) 3 (3.2)
Fatigue 29 (29.3) 3 (3.0) 40 (42.1) 4 (4.2)
Vomiting 28 (28.3) 1 (1.0) 42 (44.2) 6 (6.3)
Headache 21 (21.2) 3 (3.0) 23 (24.2) 2 (2.1)
Pyrexia 16 (16.2) 1 (1.0) 10 (10.5) 0 (0.0)
Constipation 12 (12.1) 0 (0.0) 45 (47.4) 1 (1.1)
Serious adverse 
events
Discontinuations 
due to AEs
n = 95
This table includes adverse events with an onset date between the date of the first dose and 30 days following the 
date of the last dose of study treatment (unless the patient switched to selumetinib earlier than 30 days following 
discontinuation of temozolomide).
32 (32.3) 16 (16.8)
10 (10.1) 2 (2.1)
Number (%) of patients
Selumetinib
n = 99
Temozolomide
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Number of patients enrolled
N=239
Number of patients randomized
n=200
Selumetinib
n=104
Temozolomide
n=96
Received selumetinib
n=99
Received temozolomide
n=95
Ongoing on initial 
study treatment (n=3)
Ongoing on initial 
study treatment (n=3)
Not randomized (n=39) due to:
• Incorrect enrollment (n=27)
• Voluntary discontinuation (n=7)
• Other (n=3)
• Safety reasons (n=1)
• Subject lost to follow-up (n=1)
Patients (n=5) did not 
receive treatment due to:
• Incorrect enrollment (n=2)
• Unknown (n=2)
• Other (n=1)
One patient did not 
receive treatment due 
to incorrect enrollment
Discontinued initial treatment (n=92) due to:
• Disease progression (n=81)
• Adverse event (n=2)
• Othera (n=9)
Discontinued initial treatment (n=96) due to:
• Disease progression (n=78)
• Adverse event (n=10)
• Othera (n=3)
• Patient not willing to continue study 
  treatment (n=5)
Switched to selumetinib (n=59):
• Objective disease progression (n=54)
• Incorrect switching (n=5)
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Number of patients enrolled
N=239
Number of patients randomized
n=200
Selumetinib
n=104
Temozolomide
n=96
Received selumetinib
n=99
Received temozolomide
n=95
Ongoing on initial 
study treatment (n=3)
Ongoing on initial 
study treatment (n=3)
Not randomized (n=39) due to:
• Incorrect enrollment (n=27)
• Voluntary discontinuation (n=7)
• Other (n=3)
• Safety reasons (n=1)
• Subject lost to follow-up (n=1)
Patients (n=5) did not 
receive treatment due to:
• Incorrect enrollment (n=2)
• Unknown (n=2)
• Other (n=1)
One patient did not 
receive treatment due 
to incorrect enrollment
Discontinued initial treatment (n=92) due to:
• Disease progression (n=81)
• Adverse event (n=2)
• Othera (n=9)
Discontinued initial treatment (n=96) due to:
• Disease progression (n=78)
• Adverse event (n=10)
• Othera (n=3)
• Patient not willing to continue study 
  treatment (n=5)
Switched to selumetinib (n=59):
• Objective disease progression (n=54)
• Incorrect switching (n=5)
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